An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants

HIGHLIGHTS

SUMMARY

The authors investigated the protective efficacy of Coronavirus disease-2019 (COVID-19), which is caused by infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread worldwide due to the lack of specific immunity against SARS-CoV-2 in most humans (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020; Zhou et_al, 2020). The spike (S) protein on the virion surface mediates SARS-CoV-2 entry into target cells through binding to the host cell receptor, angiotensinconverting enzyme 2 (ACE2) (Hoffmann et_al, 2020; Wrapp et_al, 2020). Consistent with . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.